Clinical Study Results
In Part 2:
• The adverse reactions in participants who got only durvalumab were hot flash, back pain,
and high levels of calcium in the blood. These happened in 1 participant with bladder
cancer.
• The most common adverse reaction in participants who got tremelimumab and
durvalumab were diarrhea and low levels of thyroid hormone.
The table below shows the adverse reactions that happened. These adverse reactions
may have occurred in more than one participant.
Adverse reactions during Part 2 with tremelimumab and durvalumab
Bladder cancer Breast cancer Pancreatic cancer
(out of (out of (out of
Adverse reaction 7 participants) 5 participants) 4 participants)
Low levels of
0% (0) 20.0% (1) 25.0% (1)
thyroid hormone
Diarrhea 0% (0) 20.0% (1) 25.0% (1)
Skin itching 0% (0) 0% (0) 25.0% (1)
Diarrhea with
0% (0) 20.0% (1) 0% (0)
bleeding
Blood test showing
raised enzyme 0% (0) 20.0% (1) 0% (0)
(amylase)
Rash 14.3% (1) 0% (0) 25.0% (1)
Tiredness 14.3% (1) 0% (0) 0% (0)
10